a:head Receives FFG Funding for Alzheimer’s Disease Neuroinflammation Research
a:head bio has been awarded EUR 1 million of public funding from the Austrian Research Promotion Agency (FFG) under the Austria Life Science Program for a project focused on developing a human neuroimmune organoid platform for Alzheimer’s disease research.
The project aims to establish a robust human brain organoid model containing functional microglia, enabling the study of neuroimmune interactions and disease-relevant inflammation in a scalable format. Using synthetic Aβ and Tau aggregates as well as brain-derived material from healthy donors and Alzheimer’s disease patients, the platform will be evaluated for its ability to reproduce key features of Alzheimer’s pathology, including microglial activation, inflammatory signalling, pathological protein accumulation, and neuronal dysfunction.
“Human-relevant models are essential for understanding the role of neuroinflammation in Alzheimer’s disease and for improving the translation of new therapeutic approaches,” said Josh Bagley, CSO of a:head bio. “This project will help to establish a powerful platform for studying neuroimmune mechanisms and evaluating disease-associated responses in a controlled human system.”
By expanding a:head bio’s capabilities into neurodegenerative disease research, the project opens new business opportunities in the growing neurodegeneration market and further strengthens the company’s position as the pioneer of advanced human organoid-based solutions for drug discovery and development.
About a:head bio AG
a:head bio AG is an Austrian biotech company uncovering novel CNS therapeutics by employing a proprietary drug development engine with true physiological relevance. Unlike traditional strategies using molecular targets and animal models, the venture recreates central nervous system diseases in human brain tissue at scale. This biomedical revolution fuses cutting-edge science using cell reprogramming, gene editing, state-of-the-art 3D culture technology, and digital biology. The company applies deep AI-driven analysis to uncover complex disease signatures and push disease model sophistication ahead to create unrivaled opportunities in CNS drug discovery.
Kontakt
a:head bio AG
Dr.-Bohr-Gasse 7, VBC6
1030 Vienna, Austria
Oliver Szolar, CEO
oliver.szolar@aheadbio.com
+43 1 3660519
www.aheadbio.com